Bivalirudin

Loading...

References

  1. Sunil V Rao. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. Journal of the American College of Cardiology, 2025
  2. J. D. Douketis. Perioperative Management of Patients Taking Direct Oral Anticoagulants: A Review.. JAMA, 2024
  3. B. Bikdeli. Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials. Circulation, 2023
  4. Yi Li. Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial. The Lancet, 2022
  5. Jennifer S Lawton. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. Journal of the American College of Cardiology, 2021
  6. D. Erlinge. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. The New England Journal of Medicine, 2017
  7. Emily Perdoncin. The comparative efficacy of bivalirudin is markedly attenuated by use of radial access: insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium.. European heart journal, 2016
  8. Yaling Han. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.. JAMA, 2015